# Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

> **NCT02670434** · PHASE3 · WITHDRAWN · sponsor: **Kowa Research Institute, Inc.**

## Conditions studied

- Hyperlipidemia
- Dyslipidemia

## Interventions

- **DRUG:** NK-104-CR
- **DRUG:** Placebo
- **DRUG:** Livalo

## Key facts

- **NCT ID:** NCT02670434
- **Lead sponsor:** Kowa Research Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2017-07
- **Final completion:** 2017-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670434, "Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02670434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*